drugset / Trial / NCT07183852
Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the feasibility, safety and tolerability of locoregional or systemic administration of autologous tumor infiltrating lymphocytes in patients with metastatic melanoma
Timeline
- Start
- 2026-03
- Primary completion
- 2028-03
- Completion
- 2033-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | Other |
| Background | Melphalan | Small molecule | 1 mg/kg | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | 2e+06 iu | Subcutaneous |